The Cannigma

MAY 19, 2021

Medical : Illegal Recreational : Illegal *CBD products are legal in Japan, as long as they contain no THC whatsoever and are not made from cannabis flower. Since 2016, the country has permitted the sale of CBD and some Japanese companies produce cannabidiol products as well. How much does CBD cost in Japan? Shutterstock).

Law 137

Law Legalization Clinical Trials CBD 137

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. These effects are shared by THC and CBD, but are typically less potent. However the combination of CBN and CBD produced longer-lasting results, supporting the entourage effect theory.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

The Joint Blog

APRIL 22, 2022

Cannabidiol, also popularly known as CBD, is a chemical compound derived from cannabis Sativa plants. There are multiple ways to ingest this oil; one can apply it topically, consume it through smoke inhalation or in the form of edible. Many companies offer CBD oil in multiple forms for general use. Forms of CBD.

Oil 26

Oil CBD Topical Clinical Trials 26

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

The two active cannabinoids in marijuana are cannabidiol (CBD) and tetrahydrocannabinol (THC), the latter of which causes psychoactive effects while the former does not. CBD seems to help the body’s natural endocannabinoid system return to normalcy and function better. CBD for Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Kind Meds (Cannabis Education Blog)

NOVEMBER 16, 2022

While CBN is a cannabinoid like THC and CBD, it has different traits, effects, and properties than THC and CBD. THC and CBD are two common cannabinoid names, but they aren’t the only compounds found in the cannabis plant. While CBN is a cannabinoid, it is not as well-known as THC and CBD. capsule, oil, topical, edible).

Sleep 94

Sleep Cannabinoids THC CBD 94

Canna Care Docs

DECEMBER 16, 2020

Among the 100-plus chemicals called cannabinoids in the cannabis plant, the two that are best known for their medicinal benefits are tetrahydrocannabinol (THC) and cannabidiol (CBD). While many of their effects and uses overlap, the biggest difference between the two is that THC produces a “high” while CBD does not. Chronic pain.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

FEBRUARY 3, 2022

Due to the rising adoption of cannabidiol (CBD) based products to treat ailments, the global cannabis market is expected to grow significantly during the forecast period. Based on route of administration, the market is segmented into oral, topical, inhalation, rectal, sublingual.

Indica 52

Indica Oil Legalization Research and Development 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. E-commerce sales of CBD in the U.S. Consumers spent roughly $31.3

CBD 144

CBD Seed-To-Sale Food Access 144

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Epidiolex has received FDA approval to treat Dravet Syndrome and Lennox-Gestaut Syndrome; two very rare forms of epilepsy that manifest in early childhood. Instead, Epidiolex contains refined cannabidiol (CBD), a compound that provides pain relief and anti-seizure properties without the typical effects associated with marijuana use.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

JANUARY 24, 2022

DUBLIN–(BUSINESS WIRE)–The “North America Legal Cannabis Market Size, Share & Trends Analysis Report by Sources (Marijuana, Hemp), by Derivatives (CBD, THC), by End Use (Medical, Recreational), and Segment Forecasts, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. from 2022 to 2028.

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Cannabidiol (CBD) and ALS. High in THC.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Virpax is initially seeking FDA approval of its three patented drug delivery platforms. About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

SEPTEMBER 20, 2021

(“Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. VRP324 uses a preassembled device and cartridge to propel the CBD powder formulation into the nose to the brain via the olfactory nerve/bulb.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

MGC Pharma

FEBRUARY 20, 2018

Cannabis is an effective tool for the treatment of topical skin conditions In a recent study by undertaken by MGC Pharma, our dermatologists found that CBD is effective in providing relief for relief for dry, red, flakey, oily and acne prone skin through CBD skincare.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

SEPTEMBER 9, 2021

Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. Key Topics Covered: Chapter 1 Methodology and Scope. Chapter 2 Executive Summary. Market Segmentation. Switzerland.

Recreational 95

Recreational Hemp THC Legalization 95

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Epoladerm™ Epoladerm is a diclofenac topical spray film product candidate that is being developed for pain associated with osteoarthritis of the knee. to conduct this study in Canada.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 1, 2021

Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Virpax is developing branded, non-addictive pain management and neurological product candidates using its proprietary technologies to optimize and target drug delivery.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 12, 2019

Cannabidiol (CBD), a compound produced by the cannabis plant, is quickly growing in popularity and headed toward mainstream acceptance. CBD oil is finding its way into a variety of products, from tinctures and drops to CBD-infused edibles and CBD balms, as well as a wide range of cosmetics. A Short History of CBD Oil.

CBD 40

CBD Terpenes Oil Tincture 40

Cannabis Law Report

NOVEMBER 10, 2021

Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). Refractory paediatric epilepsy. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

DECEMBER 22, 2021

We have autism and epilepsy. For example, when they open up the CBD-only market, products that will not contain THC, then they will probably find a solution there. One was to open up the ability to receive CBD oils from certain age. I don’t know if we’ll have topicals initially, or later on.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

OCTOBER 17, 2019

Retailers such as Walgreens, CVS, Rite Aid, Kroger, Safeway, Nordstrom, and DSW are selling or plan to sell CBD-infused topical lotions, cosmetics, and even edibles where they are legally able to do so. Not only are makers of foods, health and beauty products, and supplements interested in CBD and THC.

Law 40

Law Seed-To-Sale Hemp Recreational 40